Plasminogen activator inhibitor-1 inhibitors: a patent review (2006-present)

被引:48
作者
Fortenberry, Yolanda M. [1 ]
机构
[1] Johns Hopkins Univ, Sch Med, Dept Pediat, Div Hematol, Baltimore, MD 21205 USA
关键词
antagonist; inhibitors; PAI-1; plasminogen; serpin; RENAL-CELL CARCINOMA; INSULIN-RESISTANCE ATHEROSCLEROSIS; INDUCED PULMONARY-FIBROSIS; RECEPTOR-RELATED PROTEIN; PAI-1; GENE-EXPRESSION; HUMAN ADIPOSE-TISSUE; BILE-DUCT LIGATION; TRANSGENIC MICE; CARDIOVASCULAR-DISEASE; MYOCARDIAL-INFARCTION;
D O I
10.1517/13543776.2013.782393
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Introduction: Plasminogen activator inhibitor-1 (PAI-1), the serine protease inhibitor (serpin), binds to and inhibits the plasminogen activators-tissue-type plasminogen activator (tPA) and the urokinase-type plasminogen activator (uPA). This results in both a decrease in plasmin production and a decrease in the dissolution of fibrin clots. Elevated levels of PAI-1 are correlated with an increased risk for cardiovascular disease and have been linked to obesity and metabolic syndrome. Consequently, the pharmacological suppression of PAI-1 might prevent or treat vascular disease. Areas covered: This article provides an overview of the patenting activity on PAI-1 inhibitors. Patents filed by pharmaceutical companies or individual research groups are described, and the biological and biochemical evaluation of the inhibitors, including in vitro and in vivo studies, is discussed. An overview of patents pertaining to using these inhibitors for treating various diseases is also included. Expert opinion: Although there is still no PAI-1 inhibitor being evaluated in a clinical setting or approved for human therapy, research in this field has progressed, and promising new compounds have been designed. Most research has focused on improving the pharmacological profile of these compounds, which will hopefully allow them to proceed to clinical studies. Despite the need for further testing and research, the potential use of PAI-1 inhibitors for treating cardiovascular disease appears quite promising.
引用
收藏
页码:801 / 815
页数:15
相关论文
共 117 条
  • [1] Rasminogen activator inhibitor-1, adipose tissue and insulin resistance
    Alessi, Marie-Christine
    Poggi, Marjorie
    Juhan-Vague, Irene
    [J]. CURRENT OPINION IN LIPIDOLOGY, 2007, 18 (03) : 240 - 245
  • [2] PAI-1 and the metabolic syndrome - Links, causes, and consequences
    Alessi, Marie-Christine
    Juhan-Vague, Irene
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2006, 26 (10) : 2200 - 2207
  • [3] Plasminogen activator inhibitor 1, transforming growth factor-β1, and BMI are closely associated in human adipose tissue during morbid obesity
    Alessi, MC
    Bastelica, D
    Morange, P
    Berthet, B
    Leduc, I
    Verdier, M
    Geel, O
    Juhan-Vague, I
    [J]. DIABETES, 2000, 49 (08) : 1374 - 1380
  • [4] Production of plasminogen activator inhibitor 1 by human adipose tissue - Possible link between visceral fat accumulation and vascular disease
    Alessi, MC
    Peiretti, F
    Morange, P
    Henry, M
    Nalbone, G
    JuhanVague, I
    [J]. DIABETES, 1997, 46 (05) : 860 - 867
  • [5] PAI-1 - A potential therapeutic target in cancer
    Andreasen, Peter A.
    [J]. CURRENT DRUG TARGETS, 2007, 8 (09) : 1030 - 1041
  • [6] PAI-1-derived peptide EEIIMD prevents impairment of cerebrovasodilation by augmenting p38 MAPK upregulation after cerebral hypoxia/ischemia
    Armstead, William M.
    Riley, John
    Kiessling, J. Willis
    Cines, Douglas B.
    Higazi, Abd Al-Roof
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2010, 299 (01): : H76 - H80
  • [7] The antifibrotic effects of plasminogen activation occur via prostaglandin E2 synthesis in humans and mice
    Bauman, Kristy A.
    Wettlaufer, Scott H.
    Okunishi, Katsuhide
    Vannella, Kevin M.
    Stoolman, Joshua S.
    Huang, Steven K.
    Courey, Anthony J.
    White, Eric S.
    Hogaboam, Cory M.
    Simon, Richard H.
    Toews, Galen B.
    Sisson, Thomas H.
    Moore, Bethany B.
    Peters-Golden, Marc
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2010, 120 (06) : 1950 - 1960
  • [8] Metabolic Factors, Adipose Tissue, and Plasminogen Activator Inhibitor-1 Levels in Type 2 Diabetes Findings From the Look AHEAD Study
    Belalcazar, L. Maria
    Ballantyne, Christie M.
    Lang, Wei
    Haffner, Steven M.
    Rushing, Julia
    Schwenke, Dawn C.
    Pi-Sunyer, F. Xavier
    Tracy, Russell P.
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2011, 31 (07) : 1689 - U493
  • [9] The plasminogen activator inhibitor "paradox" in cancer
    Binder, Bernd R.
    Mihaly, Judit
    [J]. IMMUNOLOGY LETTERS, 2008, 118 (02) : 116 - 124
  • [10] Antimetastatic Potential of PAI-1-Specific RNA Aptamers
    Blake, Charlene M.
    Sullenger, Bruce A.
    Lawrence, Daniel A.
    Fortenberry, Yolanda M.
    [J]. OLIGONUCLEOTIDES, 2009, 19 (02) : 117 - 128